Superscan prostate cancer
Superscan prostate cancer. Prostate cancer (46/80) was the most common cause of superscan appearance followed by breast cancer (10/80). 1 About 40–60% of the injected Tc-99m MDP is excreted in the urine. The patient responded well to definitive treatment, exhibiting clinical improvement based on decreased PSA levels and CT findings in 6-month follow-up. dSuperscan status was determined via Technetium-99m bone scan. This type of scan results in the characteristically high boneto-soft tissue ratio in image intensity. Jan 1, 2021 · This study aims to evaluate the accuracy of a superscan as defined above, with combination of 3D SPECT/CT reconstructed images for detecting and diagnosing bone metastases in prostate cancer patients. g. Location The distribution of skeletal metastases roughly mirrors the distribution of red marrow , presumably reflecting increased blood flow in red marrow compared to yellow marrow 8 : Nov 23, 2023 · Purpose This study aims to establish and validate a new diagnosis model called P. 6% in patients with gastric cancer and up to 23% in a cohort of prostate cancer patients. A superscan pattern on the initial whole-body bone scan suggested extensive disease. This entry was posted in Endocrine Ligand PET/CT in Prostate Cancer-Diagnostic Criteria and Its Significance Abstract Superscan in 68Ga-PSMA ligand PET/CT is not very commonly encountered in prostate cancer patients. To evaluate the accuracy of standard whole body planar images (superscan) in conjunction with xSPECT reconstruction images in detecting and diagnosing bone metastases in patients with prostate cancer. Incidence of superscan in prostate cancer was 14. Howard Scher of Memorial Sloan Kettering presented the Prostate Cancer Working Group 3 (PCWG3) Consensus Guidelines, an update from the previously published Feb 21, 2014 · Positron emission tomography/computed tomography (PET/CT) is widely used in prostate cancer to evaluate the localized tumor burden and detect symptomatic metastatic lesions early. Although PET radiotracers generally have higher sensitivity and spatial resolution, SPECT tracers can be an effective alternative when PET/CT systems are unavailable in the clinical setting. Jan 1, 2021 · A study of 307 prostate cancer patients reported that 15% demonstrated superscan appearances, of which 72% of the same group (15%) had serum PSA levels of 178 ng/ml and 122 ng/ml in symptomatic and asymptomatic patients respectively (Manohar et al. Apr 19, 2022 · Imaging of metastatic castrate-resistant prostate cancer to select patients suitable for peptide receptor radioligand therapy can be performed with both SPECT and PET PSMA radiotracers. 2020. Mar 1, 2011 · This is a report of bone scintigraphy demonstrating superimposed metastatic and metabolic superscan in a patient with prostate cancer, who subsequently developed renal osteodystrophy. We present a case Prostate cancer is one of the most common cancers affecting men. 73% (33/46) prostate cancer patients with superscan had Gleason score of 8 and above 8 with mean serum prostate-specific Aug 14, 2023 · If the kidneys and bladder are not seen, this should raise suspicion of the so-called “superscan. 68 Ga-PSMA ligand in PET/CT revealed a PSMA over expression of diffuse sclerotic lesions extended to axial and appendicular Dec 14, 2022 · Lung cancer, breast cancer, renal cell carcinoma, and prostate cancer account for ~80% of all bone metastases 1. A. Jun 23, 2021 · Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Intense osteoblastic activity in the bones causes diminished renal and background soft t Jun 14, 2024 · Prostate cancer that spreads to the bones can cause pain and broken bones. 18F-FDG is the Jan 19, 2022 · A superscan is an imaging appearance on a Tc-99m diphosphonate bone scan which occurs as a result of a high ratio of bone to soft tissue tracer accumulation. Offering breakthrough diagnostics for prostate cancer treatment Prostate cancer is one of the most common cancers in men. The new prostate-specific membrane antigen (PSMA) PET imaging will significantly improve how prostate cancer is detected and treated. }, author={Ew-Jun Chen and Teik Hin Tan and Ming Tsuey Chew}, journal={Radiation Physics and Chemistry Sep 26, 2023 · This report presents the imaging findings in a patient with advanced prostate cancer and bone metastases. Jan 1, 2024 · Introduction. doi: 10. score for clinically significant prostate cancer (csPCa). Fig. 3% in a cohort of mixed cancer types up to 2. We present a 70-year-old patient with an elevated PSA serum level of 638 ng/mL after chemo-therapy for prostate cancer. KEYWORDS benign, bone scintigraphy, cancer, metabolic Sep 26, 2023 · Superscan Treatment response a b s t r a c t This report presents the imaging findings in a patient with advanced prostate cancer and bone metastases. Etiology. gastric cancer and up to 23% in a cohort of prostate cancer patients. Jan 1, 2021 · DOI: 10. 178. Mar 1, 2003 · Superscan: Superiority of xSPECT/CT over OSEM SPECT/CT in bone scans of prostate cancer patients. 2%)), high C reactive protein (4. 68Ga-PSMA-11 If a patient has lower back pain, an elevated PSA, and a positive prostate biopsy with a Gleason score of 8, and he also has a positive bone scan showing accumulation of tracer in his lower spine and pelvis, it’s a pretty safe bet that the bone scan is showing metastatic prostate cancer. g The appearance of a metastatic superscan differs from that of a metabolic superscan. Oncol. 1,2,3 After lungs and liver, bone is the third most common site of metastasis; 80% of bone malignancies are Jan 3, 2018 · Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e. 98% (46/307), and 71. radphyschem. In these retrospective case series, we performed SPECT with A 75-year-old man presented with a 2-month history of worsening chest and back pain. With metabolic bone disease, the increased uptake is often more homogeneous and may extend to the distal appendicular skeleton. 1 Technique Among papers with malignant cause, prostate cancer was the most common cause, followed by gastric cancer. Out of 6027 patients referred for bone scan, 307 patients had prostate cancer on histopathological examination. Jul 14, 2024 · Keywords: acute lymphoblastic leukemia, 18 F-FDG PET/CT, bone marrow, diffuse uptake, superscan. 3389/fonc. KEYWORDS benign, bone scintigraphy, cancer, metabolic Jun 19, 2018 · Superscan in 68 Ga-PSMA ligand PET/CT is not very commonly encountered in prostate cancer patients. 73% (33/46) prostate cancer patients with superscan had Gleason score of 8 and above 8 with mean serum prostate-specific Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan Krishan Kant Agarwal , Madhavi Tripathi , Rajeev Kumar , and Chandrasekhar Bal Dec 28, 2023 · Prostate cancer is the second most common malignancy in men worldwide, with a good prognosis when is detected and treated in early stages, but, when it presents progression to castration-resistant metastatic prostate cancer, most of the cases will have bone metastasis, decreasing the quality of life … In the US, about 350,000 patients with cancer will develop bone metastases each year. 1016/j. This may assist the identification of this relatively uncommon diffuse metastatic disease in men with prostate cancer and reduce the number of investigations that … Apr 18, 2023 · Superscan is most frequently seen in prostate cancer, but numerous other cancers and metabolic bone diseases can cause superscan, which should be kept in mind when encountering an unexpected superscan on BS. However, patients with diffuse bone involvement, diagnosed with a "superscan" by bone s … Out of 6027 patients referred for bone scan, 307 patients had prostate cancer on histopathological examination. The frequency of superscans ranged from 1. @article{Chen2021SuperscanSO, title={Superscan: Superiority of xSPECT/CT over OSEM SPECT/CT in bone scans of prostate cancer patients. 108998 Corpus ID: 219762264; Superscan: Superiority of xSPECT/CT over OSEM SPECT/CT in bone scans of prostate cancer patients. 1401453 The <sup>177</sup>Lu-labeled prostate-specific membrane antigen (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer is under investigation in a phase III trial (VISION: NCT03511664). Diagnosis certain Share Add to . 17. Here we present the case of a 41 year old woman with carcinoma colon with metastatic superscan on 99m Tc-MDP bone scintigraphy, a very rare cause for metastatic superscan. With metastatic disease (most commonly prostate or breast cancer), the uptake is heterogeneous or patchy and favors the axial skeleton. }, author={Ew-Jun Chen and Teik Hin Tan and Ming Tsuey Chew}, journal={Radiation Physics and Chemistry Jun 2, 2015 · ASCO - Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration resistant prostate cancer - Session Highlights Published 02 June 2015 CHICAGO, IL USA (UroToday. Primary Endpoint: PSA50 Response • PSA50 was achieved in 10/20 participants (50%), regardless of prior Lu treatment (Figure 4) Apr 18, 2023 · Superscan is most frequently seen in prostate cancer, but numerous other cancers and metabolic bone diseases can cause superscan, which should be kept in mind when encountering an unexpected superscan on BS. Once prostate cancer has spread to other areas of the body, it may still respond to treatment and may be controlled, but it's unlikely to be cured. Lutetium-177 (177 Lu)–PSMA-617 is a radioligand therapy that delivers Dec 28, 2023 · We describe a case series of seven patients with prostate cancer from the National Institute of Cancerology in Colombia, in which a super scan pattern was found in the evaluation with 68 Ga-PSMA PET/CT, proposing the suppression of uptake in the intestine, liver, spleen, lacrimal and salivary glands as the main criteria for its definition, and Jan 19, 2022 · A superscan is an imaging appearance on a Tc-99m diphosphonate bone scan which occurs as a result of a high ratio of bone to soft tissue tracer accumulation. No study has specifically assessed its safety in patients with extensive skeletal metastases of mCRPC. , 2017). 2 Therefore, significant renal and bladder radioactivity are normal in most scans. Jan 24, 2016 · A 72-year-old man with a history of metastatic prostate cancer is referred for a bone scan because of pain in the left shoulder and lower neck . }, author={Ew-Jun Chen and Teik Hin Tan and Ming Tsuey Chew}, journal={Radiation Physics and Chemistry Jan 1, 2021 · DOI: 10. Superscan met prostate cancer. 68 Ga-PSMA ligand in PET/CT revealed a PSMA over expression of diffuse sclerotic lesions extended to axial and appendicular This report presents the imaging findings in a patient with advanced prostate cancer and bone metastases. 73% (33/46) prostate cancer patients with superscan had Gleason score of 8 and above 8 with Nov 21, 2020 · Prostate Cancer UK Online Community » Treatment » Advanced or metastatic cancer » Dad diagnosed with advanced PC, 'superscan' shows mets in over 75% of bones, nodules in lung too Join the online community now. 5 mg/dL), high serum ferritin 18F-FDG PET/CT of a patient with inflammatory lower back pain reveals diffuse bony metastases, similar to the “superscan” found on a 99mTc-methylene diphosphonate scintigraphy, and also demonstrates a prostatic lesion which appears to be a poorly differentiated prostate adenocarcinoma. Prostate cancer is the most common cancer in men in the United States. Out of 307 patients with prostate cancer, 46 had superscan appearance. 2024. 1 There is a wide range gastric cancer and up to 23% in a cohort of prostate cancer patients. Apr 29, 2019 · Up to 90% of men with metastatic castration-resistant prostate cancer (mCRPC) will have a distribution of disease that includes bone metastases demonstrated on a Technetium-99m (99mTc-MDP) bone Dec 1, 2023 · This report presents the imaging findings in a patient with advanced prostate cancer and bone metastases. A bone scan with diffused increased skeletal tracer uptake relative to soft tissue, combined with faint renal activity is known as a superscan. ” A superscan implies diffusely increased osseous uptake due to metastatic disease (most commonly breast or prostate cancer) or metabolic bone disease which is so intense that little or no renal excretion of the radiotracer occurs. The pattern of diffuse increased skeletal uptake with no tracer seen in the kidneys/bladder is called a "superscan". Superscan Superscan: intense symmetric uptake of radiotracer by the skeletal system with relative decreased uptake by the bladder, kidneys, and soft tissues Differential diagnosis for superscan: • Metastatic disease (prostate, breast, transitional cell carcinoma) • Metabolic bone disease (hyperparathyroidism, renal osteodystrophy, osteomalacia) The whole-body image count alone, with little or no additional processing, is a helpful discriminator for the nuclear medicine superscan. Ew-JunChen, Teik HinTan, Ming TsueyChew 2021 | Radiation Physics and Chemistry, Vol. This patient had a known history of prostate cancer with an elevated PSA of 45 ng/mL. F-FDG PET/CT of a patient with inflammatory lower back pain reveals diffuse bony metastases, similar to the "superscan" found on a Tc-methylene diphosphonate scintigraphy, and also demonstrates a prostatic lesion which appears to be a poorly differentiated prostate adenocarcinoma. Mar 6, 2020 · Superscan metastatic prostate cancer. Citation: Hu Y, Dai W, Wang P, Feng Y, Feng H and Li J (2024) Case report: 18 F-FDG PET/CT skeletal superscan-like in an adult patient with acute lymphoblastic leukemia. Case contributed by Zeyad Al-Ogaili. A superscan pattern on the initial whole-body This is a report of bone scintigraphy demonstrating superimposed metastatic and metabolic superscan in a patient with prostate cancer, who subsequently developed renal osteodystrophy. , docetaxel and cabazitaxel), immunotherapy (e. com) - Dr. Age, prostate-specific antigen (PSA), free/total PSA (f/tPSA), PSA density (PSAD), peripheral zone volume ratio (PZ-ratio), and adjusted PSAD of PZ (aPSADPZ) were Feb 2, 2022 · Superscan Appearance of 68 Ga PSMA PET/CT in a Patient with Refractory Prostate Cancer Refrakter Bir Prostat Karsinomu Olgusunun 68 Ga PSMA PET/BT’de Superscan Görünümü Zehra Pınar Koç , 1, * Pınar Pelin Özcan , 1 Vehbi Erçolak , 2 and Mehmet Reyhan 3 Following an amendment, superscan participants are excluded. We present a 70-year-old patient with an elevated PSA serum level of 638 ng/mL after chemotherapy for prostate cancer. Apr 6, 2022 · Purpose Actinium-225-labeled prostate-specific membrane antigen ([225Ac]Ac-PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Physical examination revealed generalised bone tenderness with associated indirect pain; digital rectal examination indicated asymmetric prostatic induration. DOI: 10. Z. The FDA approved the drug for positron emission tomography (PET) imaging of PSMA-positive lesions in men with prostate cancer. Bone scan is part of the staging modality commonly used to evaluate bone metastasis. Conclusion: Superscan is most frequently seen in prostate cancer, but numerous other cancers and metabolic bone diseases can cause superscan, which should be kept in mind when encountering an unexpected superscan on BS. Pathology. We aimed to investigate the hematologic toxicity and efficacy of [225Ac]Ac-PSMA-617 therapy in patients with Furthermore, the criteria of a superscan can sometimes yield inconclusive results. Prostate cancer is the most common malignancy associated with superscan along with others such as lung cancer, breast cancer and haematological malignancies. Methods The demographic and clinical characteristics of 956 patients were recorded. Intense osteoblastic activity in the bones causes diminished renal and background soft tissue uptake. Two years after the first bone scintigraphy showing multiple metastases, the patient developed renal insufficiency, hyperphosphoremia, and hypocalcemia. The patient responded well to definitive treatment, exhibiting clinical improvement based on decreased PSA le … The superscan effect presents a technical challenge in the evaluation of lesions on bone scans in prostate cancer clinical trials. }, author={Ew-Jun Chen and Teik Hin Tan and Ming Tsuey Chew}, journal={Radiation Physics and Chemistry Jun 19, 2018 · Superscan in 68 Ga-PSMA ligand PET/CT is not very commonly encountered in prostate cancer patients. Front. May 28, 2020 · Incidence of superscan in prostate cancer was 14. 68Ga-PSMA ligand in PET/CT revealed Superscan due to metastatic prostate cancer. Sep 16, 2014 · Super bone scan is a special condition of extremely high bone uptake relative to soft tissue with absent renal radioactivity visualisation (‘absent kidney sign’). Incontinence. Feb 1, 2008 · The most significant factors associated with the «superscan» scintigraphy phenomenon in prostate cancer patients were the primary tumor extension, high PSA level and low-grade tumors. eCarboplatin was given as part of a taxane regimen. However, a primary concern are false negatives associated with bone scans, where diffuse metastasis is Apr 30, 2020 · Incidence of superscan in prostate cancer was 14. Prostate cancer (46/80) was the most common cause of superscan appearance followed by breast cancer (10/80). This appearance can result from a range of causes: A technetium-99m methyl diphosphonate bone superscan demonstrating intense, diffuse uptake in the axial and proximal appendicular skeleton as well as more focal uptake in the calvarium in this patient with metastatic prostate adenocarcinoma. Citation, DOI, disclosures and case data. 14:1401453. 1 While the overall prognosis of men diagnosed with prostate cancer is excellent, prostate cancer is also the second leading cause of cancer-related mortality in men in the United States, as a large subset of patients will have progressive disease to which they will ultimately succumb. Laboratory examination revealed high serum alkaline phosphatase (1348 U/L (bone type, 73. Posted on March 6, 2020 October 15, 2023 by Edward Gillis. Both prostate cancer and its treatment can cause urinary incontinence. kbt aksqa psbfm obcmvq wydad fmag yzarwk jgxgsfr zllkcf dpllcwc